<DOC>
	<DOCNO>NCT00749164</DOCNO>
	<brief_summary>Now commonly accept MSC produce immune-tolerant environment different setting . It show ( mainly BM-MSC ) MSC down-regulate T cell activation . This characteristic BM derive MSC already clinical implication show potent effectiveness prophylaxis treatment resistant GvHD . Ongoing clinical trial use bone marrow MSC treatment steroid resistant GvHD successfully run bone marrow donor registry include BM-MSC material donation . According preclinical study MSC cell marrow , placenta , umbilical cord vessel demonstrate similar pronounce immunosuppressive effect autologous allogeneic lymphocyte . Our preliminary clinical experience show BM-MSC effective tool treatment steroid resistant GVHD . Present study aim demonstrate human UC-MSC vivo immunosuppressive effect use GVHD treatment</brief_summary>
	<brief_title>Allogeneic Mesenchymal Stem Cell Graft-Versus-Host Disease Treatment</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Inclusion criterion : 1 . Informed consent . 2 . Any patient undergone allogeneic stem cell transplantation steroid refractory grade IIIV acute GvHD either occur post transplant , induce donor lymphocyte infusion ( DLI ) Tcell add back . A positive biopsy GvHD require clinical sign symptom characteristic GvHD etiology exclude . 3 . Patient receive best know therapy GvHD include : . Patients must receive cyclosporine A ( trough level 150300 ng/ml ) tacrolimus ( trough level 515 ng/ml ) . ii . In addition , steroid must give , instance prednisolone â‰¥2 mg/kg/day ( equivalent dose methylprednisolone , etc . ) least 72h case progressive acute GvHD , 5 day non progressive acute GvHD . iii . Despite treatment , patient unresponsive GvHD 5 day progressive acute GvHD 72 hour . If single organ acute GvHD grade II gut liver , either progression single organ addition one two organ ; e.g. , patient grade II acute GvHD skin , GvHD intense widespread , GvHD also include liver and/or gut . iv . Patients steroid refractory GvHD fulfilling requirement mention ) c ) may treat second line therapy , e.g. , MMF , serotherapy , ECP , change CsA tacrolimus vice versa , etc . Failure respond additional treatment similar describe steroid c ) necessary enrolment study . v. Termination GvHD medication cyclosporine/tacrolimus/MMF prednisolone strongly encourage . Exclusion criteria 1 . Patients poor performance , expect survive 5 day . 2 . Patients history hypersensitivity penicillin and/or gentamycine 3 . Poor compliance . Donor inclusion criterion : 1 . MSC donor must HIV , HBs antigen , anti HBc anti HCV negative . 2 . First choice original HSC donor HLAidentical sibling donor . 3 . Second choice mismatch related unrelated donor ( instance MSC frozen leave another patient ) . 4 . Third choice emergency preexpanded third party umbilical cord/placenta derive MSC . Donor exclusion criterion : 1 . Donor 65 year age , unhealthy . 2 . Donor positive HIV , hepatitis Bs antigen , HBs , antiHBc anti HCV negative .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>Umbilical cord</keyword>
	<keyword>graft-vs-host disease</keyword>
	<keyword>Steroid resistant</keyword>
</DOC>